Biora Therapeutics Showcases Progress On BioJet Oral Delivery Platform With Largest Payload Capacity Among Ingestible Injectables At PODD Meeting; Smaller 00-Size Device Advances In Animal Models With Full Testing Expected In Q4 2024
Portfolio Pulse from Benzinga Newsdesk
Biora Therapeutics presented advancements in its BioJet oral delivery platform at the PODD meeting, highlighting its large payload capacity among ingestible injectables. The company is progressing with a smaller 00-size device in animal models, with full testing anticipated in Q4 2024.
October 28, 2024 | 12:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biora Therapeutics is advancing its BioJet oral delivery platform, which boasts the largest payload capacity among ingestible injectables. The smaller 00-size device is progressing in animal models, with full testing expected in Q4 2024.
The news highlights significant progress in Biora's BioJet platform, which could enhance its market position and attract investor interest. The anticipation of full testing in Q4 2024 suggests a positive outlook for future developments.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100